Vincent Mendiola, M.D., M.P.H.

Vincent Louie Mendiola, M.D., M.P.H., M.Sc. is an oncologist/hematologist with expertise in clinical research and public health. He values the importance of attentively listening to his patients to fully understand their concerns and values, and to better deliver personalized care and treatment through shared decision-making. He is excited by the rapid pace of progress in his field and is passionate about ensuring that his patients benefit from the latest advances.

Dr. Mendiola believes in optimizing treatment outcomes by combining clinical care, research advancement, and application of public health knowledge especially in mitigating healthcare disparities in cancer care. His 15 peer-reviewed scientific publications include health-disparity investigations showing that minorities with an aggressive form of leukemia could have outcomes equal to nonminority patients if given access to all current standards of care and new treatment approaches. He has participated in health outreach programs to the Philippines and Nicaragua and was recognized by the Department of Health for his work creating a mobile clinic for the HIV/STD Prevention Program while earning his Master of Public Health at the University of Miami.

In his free time, Dr. Louie Mendiola’s enjoys food from different cultures and playing basketball.

Awards

• Department of Health Intern Awardee; HIV/STD Prevention Program at the Dept. of Health Miami-Dade County, FL
• Provost Honors at the University of California San Diego
• Magna cum laude at the University of California San Diego

Memberships

• American Society of Clinical Oncology
• American Society of Hematology

• Mendiola VL, Chennapan K, Chen D, Rodman J, Ladha A, Tam E, Woan K, Yaghmour G. MPN-215 Outcomes of Myelofibrosis Patients Post Allogeneic-HSCT at the University of Southern California, a Retrospective Study. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S330. doi: 10.1016/S2152-2650(22)01445-8. PMID: 36163994
• MendiolaVL, Chen D, Rodman J, Yaghmour G. ALL-331Outcomes Using “Flipped” Conditioning Regimens (Fractionated Total Body Irradiation Then Fludarabine or Cyclophosphamide) for Allo-HSCT at the University of Southern California, a Retrospective Study. Clinical Lymphoma Myeloma and Leukemia, Volume 22, Supplement 2, 2022, Page S201, ISSN 2152-2650. doi.org/10.1016/S2152-2650(22)01197-1
• Mendiola VL, Ly C, Bui T, Wang J, Rodman J, Vergara-Lluri M, Woan K, Tam E, Douer D, Chaudhary P, Ladha A, Yaghmour G. Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Pegaspargase in the Era of Novel Agents; A Retrospective Study, Transplantation and Cellular Therapy, Volume 28, Issue 3, Supplement, 2022, Pages S117-S118, ISSN 2666-6367. doi.org/10.1016/S2666-6367(22)00305-0
• Mendiola VL, Ly C, Bui T, Wang J, Rodman J, Woan K, Tam E, Vergara-Lluri ME, Chaudhary PM, Douer D, Ladha A, Yaghmour G. Superior Outcomes in Hispanic Patients Compared to Non-Hispanic Patients with Ph-Negative Acute Lymphoblastic Leukemia Using the Modified Pediatric-Based University of Southern California Acute Lymphoblastic Leukemia (USC ALL) Regimen for Newly Diagnosed ALL Patients in the Era of Novel Agents; A Retrospective Study. Blood 2021; 138 (Supplement 1): 3361. doi.org/10.1182/blood-2021-150116
• Mendiola VL, Ly C, Bui T, Wang J, Rodman J, Vergara-Lluri ME, Woan K, Tam E, Chaudhary PM, Douer D, Ladha A, Yaghmour G.  n Update on Outcomes Using the USC ALL Frontline Regimen (based on CCG-1882) after Further Modification of Protocol in the Era of Novel Agents in Ph-Negative ALL Patients; A Retrospective Study. Blood 2021; 138 (Supplement 1): 3362. doi.org/10.1182/blood-2021-147124
• Mendiola VL, Kesireddy M, Suthar K, Willis M. Identifying Associations Between Clostridium difficile Infection Incidence and Cancer Patients Receiving Chemotherapy. Open Forum Infect Dis. 2019 Oct 23;6(Suppl 2):S826. doi: 10.1093/ofid/ofz360.2070.  PMCID: PMC6809772.
• Kesireddy M, Mendiola VL, Jana B, Patel S. Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms Involved. Cureus. 2019 Aug 13;11(8): e5383. doi: 10.7759/cureus.5383. PMID: 31616614; PMCID: PMC6786843.
• Mendiola VL, Kesireddy M, Jana BP. Concordance and discordance in myeloma bone marrow studies. Journal of Clinical Oncology 2019 37:15_suppl, e19508-e19508.
• Mendiola, VL, Kesireddy, M, Jana, B. Nivolumab-Induced, Late-Onset, SteroidSensitive, High-Grade Pneumonitis and Durable Tumor Suppression in Metastatic Renal Cell Carcinoma: A Case Report", Case Reports in Oncological Medicine, vol. 2019, Article ID 6759472, 5 pages, 2019.
• Kesireddy M, Mendiola VL, Jana B, et al. (August 13, 2019) Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms Involved. Cureus 11(8): e5383. doi:10.7759/cureus.5383 11. Mendiola, VL, Willis, M. Esophageal Adenocarcinoma with Extensive Metastasis to Unexpected Sites: A Case Report. Case Rep Oncol. 2018 Nov 12;11(3):742-750. doi:10.1159/000494263. eCollection 2018 Sep-Dec.
• Mendiola, VL, Qian, YW, Jana, B. Septic Shock Predisposed by an Underlying Chronic Neutrophilic Leukemia with an Atypical Presentation; A Case Report. Case Rep Oncol. 2018 Dec 20;11(3):871-879. doi: 10.1159/000495458. eCollection 2018 Sep-Dec.
• Darshi M, Mendiola VL, Mackey MR, Murphy AN, Koller A, Perkins GA, Ellisman MH, Taylor SS. ChChd3, an inner mitochondrial membrane protein, is essential for maintaining crista integrity and mitochondrial function. J Biol Chem. 2011 Jan 28;286(4):2918-32. doi: 10.1074/jbc.M110.171975. Epub 2010 Nov 16.
• Lew WY, Bayna E, Molle ED, Dalton ND, Lai NC, Bhargava V, Mendiola V, Clopton P, Tang T. Recurrent exposure to subclinical lipopolysaccharide increases mortality and induces cardiac fibrosis in mice. PLoS One. 2013 Apr 9;8(4):e61057. doi:10.1371/journal.pone.0061057. Print 2013.
• Pamenter ME, Ryu J, Hua ST, Perkins GA, Mendiola VL. DIDS Prevents Ischemic Membrane Degradation in Cultured Hippocampal Neurons by Inhibiting Matrix Metalloproteinase Release. PLoS One. 2012;7(8):e43995. doi:10.1371/journal.pone.0043995. Epub 2012 Aug 24.